Company news

Mesoblast Limited news in 2016

Mesoblast Limited's news releases, calls and decks from 2016, newest first.

View company

Mesoblast And Mallinckrodt Enter Into Agreement

December 22, 2016

MD Anderson and NIH Fund Trial Using Mesoblast Technologies

December 6, 2016

First Quarter Results On Form 6K

November 14, 2016

Successful Interim Futility Analysis In P3 Trial for GVHD

November 13, 2016

MSB Japan Strategy Highlighted At Business Council Meeting

October 12, 2016

Mesoblast Phase 2 Diabetic Kidney Disease Results Published

October 6, 2016

Preliminary Final Report (Including Appendix 4E)

August 24, 2016

MSB Strengthens US Patent Portfolio For Rheumatic Diseases

August 16, 2016

Mesoblast P2 Results Show Dose-Related Improvements In RA

August 8, 2016

MSB Back Pain Results Presented, Receive Best Science Award

August 1, 2016

Update on Heart Failure Trial and Funding of Operations

July 1, 2016

Update on Global Heart Failure Program

June 13, 2016

Suspension from Official Quotation

June 3, 2016

Mesoblast Receives $6.2m From Aus Govt For R&D

May 20, 2016

Mesoblast Provides Q3 Financial Results and Corporate Update

May 9, 2016

Mesoblast Cells Show Disease Modifying Effects on Knee OA

March 31, 2016

MSB partner jcr files for product approval

March 30, 2016

Market Exclusivity Strengthened by New USA Healthcare Act

March 30, 2016

Key Bone Repair Patent Granted in the United States

March 30, 2016

TGA Approval To Commercially Manufacture Stem Cell Products

March 30, 2016

Response to an ASX Price Query

March 30, 2016

Positive Results From Phase 2 Lumbar Fusion Trial

March 30, 2016

Phase 3 Meeting Set With FDA On Bone Marrow Regeneration

March 30, 2016

On Track for Phase 3 BMT Trial After Positive FDA Meeting

March 30, 2016

Novel Heart Attack Treatment Results Presented to US Forum

March 30, 2016

Mesoblast Targets Broader Cancer Indications

March 30, 2016

Mesoblast Clear To Proceed With Angioblast Acquisition

March 30, 2016

Appendix 4C and Clinical Trial Update

March 30, 2016

Revascor Increases Blood Supply to Damaged Heart Muscle

March 30, 2016

Mesoblast Included in S and P/ASX 200 Index

March 30, 2016

Key Product Franchises Featured at Nomura Asia Equity Forum

March 30, 2016

FDA Clears Phase 2 Trial to Treat Degenerative Disc Disease

March 30, 2016

Cardiac Events, Mortality and Hospitalization Reduced

March 30, 2016

Appendix 4D and Half Year Financial Report to 31 Dec 2010

March 30, 2016

Appendix 4C - Strong Cash Position

March 30, 2016

Positive Heart Failure Trial Results Presented to AHA

March 30, 2016

MSB and Lonza form strategic global manufacturing alliance

March 30, 2016

Licensing Executives Society Deals of Distinction Award

March 30, 2016

Intervertebral Disc Repair Phase 2 Trial Update

March 30, 2016

First Minimally Invasive Procedure for Lumbar Disc Repair

March 30, 2016

First European Trial for Heart Attack Treatment Cleared

March 30, 2016

FDA Clearance for Phase 3 Bone Marrow Transplant Trial

March 30, 2016

FDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes

March 30, 2016

Clearance for First Phase 2 Clinical Trial for Eye Diseases

March 30, 2016

Response to ASXPrice Query

March 30, 2016

Price Query

March 30, 2016

Positive Results in Phase 2 Lumbar Spinal Fusion Trial

March 30, 2016

MSB Provides Corporate Strategy For Neurologic Product

March 30, 2016

Mesoblast Corporate Overview - CEO Message to AGM

March 30, 2016

Key mpc patents granted in united states and china

March 30, 2016

Older news releases →

Decks in 2016